Skip to content

Study · Non-randomized trial · 2024

2 results

Davunetide sex-dependently boosts memory in prodromal Alzheimer's disease.

Gozes I, Blatt J, Lobyntseva A

Translational psychiatry2 Oct 2024Cited by 19 (Europe PMC)

PMID39358355 (opens in a new tab)PMCIDPMC11446927 (opens in a new tab)DOI10.1038/s41398-024-03118-0 (opens in a new tab)PepBankPUB-39358355
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with amnestic mild cognitive impairment, high-dose davunetide significantly improved digit span versus matched placebo.

    In plain wordsIn women with memory impairment, high-dose davunetide improved digit span more than matched placebo.

    Peptide
    Davunetide
    Outcome
    IncreaseDigit span
    Study

    n: not reported in source

    Comparator
    Matched placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    15 mg twice daily · intranasalAs given in this study (human).

    Source sentences

    Summary
    In a test of semantic working memory and attention (digit span), women showed a significant low-dose placebo effect, ensuing in a high dose significant davunetide improvement, over the matched placebo.
    2 context sentences
    Summary · context
    Extending these findings to prodromal Alzheimer's disease, we submitted a double-blind, placebo-controlled, 12 weeks/16 weeks follow-up, davunetide clinical trial results in amnestic mild cognitive impairment (ClinicalTrials.gov ID NCT00422981), to a sex-dependent analysis.
    Summary · context
    One hundred forty-four individuals, separated into eight groups (1:2 placebo-and 2 doses, 5 mg davunetide/daily or 15 mg davunetide/twice-daily, with matching placebo intranasal volumes), were evaluated.

Studies that did not test the peptide alone1

In this study, Davunetide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Davunetide.

  1. 02HumanNot a test of Davunetide aloneObservational studyEfficacy outcome

    In amnestic mild cognitive impairment, in a davunetide trial, dose-dependent cognitive increases on delayed visual matching to the sample were larger in men than in women.

    In plain wordsIn people with memory impairment in a davunetide trial, men showed larger dose-dependent gains than women on delayed visual matching.

    Peptide
    Davunetide
    Outcome
    IncreaseDelayed visual matching to sample
    Study

    n: not reported in source

    Comparator
    Women
    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    Significant dose-dependent cognitive increases were observed in men compared to women with a test of delayed (12 ss) visual matching to the sample.
    2 context sentences
    Summary · context
    Extending these findings to prodromal Alzheimer's disease, we submitted a double-blind, placebo-controlled, 12 weeks/16 weeks follow-up, davunetide clinical trial results in amnestic mild cognitive impairment (ClinicalTrials.gov ID NCT00422981), to a sex-dependent analysis.
    Summary · context
    One hundred forty-four individuals, separated into eight groups (1:2 placebo-and 2 doses, 5 mg davunetide/daily or 15 mg davunetide/twice-daily, with matching placebo intranasal volumes), were evaluated.

    In this study, Davunetide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Davunetide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT00422981

Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment

Allon Therapeuticsn = 144Jan 2007 to Jan 2008

Mild Cognitive Impairment, So Stated

Trial pageClinicalTrials.govUpdated 24 Oct 2012

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.